Gastro-oesophageal Reflux Disease Trial, Recruiting (NCT06660342)

Gastro-oesophageal Reflux Disease Trial, Recruiting NCT06660342 Sponsor: Phathom Pharmaceuticals, Inc. Condition: Gastro-oesophageal Reflux Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06660342 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Gord

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Women between 15 and 50 years of age
People who are currently pregnant or were recently pregnant
People who agree to take part in the study
People who agree to allow their healthcare provider(s) to share their health information with the registry
For the exposed group: people who took at least one dose of a medication called vonoprazan at some point during pregnancy
For the unexposed group: people who have not taken vonoprazan during pregnancy but who have a condition for which vonoprazan might normally be prescribed

Who may not be able to join:

People whose pregnancy has already ended before first making contact with the study coordination centre (meaning the trial site would not accept enrolment after the pregnancy outcome has already occurred)
People who were exposed during pregnancy to medications known to cause birth defects, or to experimental medications that are still being tested
People who are unable to be followed up or contacted during the study period

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 1-866-609-1612

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06660342

Sponsor: Phathom Pharmaceuticals, Inc.

Phase: Not Applicable

Status: Recruiting

Condition: Gastro-oesophageal Reflux Disease

Trial contact: 1-866-609-1612

More information: https://clinicaltrials.gov/study/NCT06660342

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Women between 15 and 50 years of age
People who are currently pregnant or were recently pregnant
People who agree to take part in the study
People who agree to allow their healthcare provider(s) to share their health information with the registry
For the exposed group: people who took at least one dose of a medication called vonoprazan at some point during pregnancy
For the unexposed group: people who have not taken vonoprazan during pregnancy but who have a condition for which vonoprazan might normally be prescribed

Who may not be able to join:

People whose pregnancy has already ended before first making contact with the study coordination centre (meaning the trial site would not accept enrolment after the pregnancy outcome has already occurred)
People who were exposed during pregnancy to medications known to cause birth defects, or to experimental medications that are still being tested
People who are unable to be followed up or contacted during the study period

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Phathom Pharmaceuticals, Inc.

Registry

ClinicalTrials.gov

Start date

15 May 2025

Est. completion

1 September 2034

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of Participants with Major Congenital Malformations (MCMs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov